Cellular therapy with ixmyelocel-T to treat critical limb ischemia: The randomized, double-blind, placebo-controlled RESTORE-CLI trial

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1280-1286

  Powell, Richard J ^a   Marston, William A ^b   Berceli, Scott A ^c   Guzman, Raul ^d   Henry, Timothy D ^e   Longcore, Amy T ^f   Stern, Theresa P ^f   Watling, Sharon ^f   Bartel, Ronnda L ^f  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e ABBOTT LABORATORIES   (United States)

^f Aastrom Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IXMYELOCEL T;

ADULT; ADVERSE OUTCOME; AGED; AMPUTATION FREE SURVIVAL; ARTICLE; BONE MARROW BIOPSY; BURNING SENSATION; CELL THERAPY; CELLULITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DOUBLE BLIND PROCEDURE; FEMALE; GANGRENE; HUMAN; LEG AMPUTATION; LEG THROMBOPHLEBITIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; SHAM PROCEDURE; SKIN REDNESS; SKIN ULCER; SURVIVAL; TIME TO FIRST OCCURRENCE TREATMENT FAILURE; TREATMENT FAILURE; URINARY TRACT INFECTION;

EID: 84861866655     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.52     Document Type: Article

References (16)

1. Hirsch, AT, Haskal, ZJ, Hertzer, NR, Bakal, CW, Creager, MA, Halperin, JL et al.; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. (2006). ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113: e463-e654.
2. Allison, MA, Ho, E, Denenberg, JO, Langer, RD, Newman, AB, Fabsitz, RR et al. (2007). Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med 32: 328-333. (Pubitemid 46441734)
3. Ostchega, Y, Paulose-Ram, R, Dillon, CF, Gu, Q and Hughes, JP (2007). Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 55: 583-589. (Pubitemid 46496588)
4. Norgren, L, Hiatt, WR, Dormandy, JA, Nehler, MR, Harris, KA, Fowkes, FG et al.; TASC II Working Group. (2007). Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl 1: S1-S75. (Pubitemid 46068992)
5. Falluji, N and Mukherjee, D (2011). Contemporary management of infrapopliteal peripheral arterial disease. Angiology 62: 490-499.
6. Powell, RJ, Simons, M, Mendelsohn, FO, Daniel, G, Henry, TD, Koga, M et al. (2008). Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118: 58-65.
7. Varu, VN, Hogg, ME and Kibbe, MR (2010). Critical limb ischemia. J Vasc Surg 51: 230-241.
8. The Critical Limb Ischemia (CLI) Performance Goals Work Group of the Society for Vascular Surgery (SVS). 〈http://Criticallimb.org〉. Accessed 01 June 2011.
9. Lawall, H, Bramlage, P and Amann, B (2010). Stem cell and progenitor cell therapy in peripheral artery disease. Thromb Haemost 103: 696-709.
10. Sprengers, RW, Lips, DJ, Moll, FL and Verhaar, MC (2008). Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 247: 411-420.
11. Tateishi-Yuyama, E, Matsubara, H, Murohara, T, Ikeda, U, Shintani, S, Masaki, H et al. for the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators (2002). Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360: 427-435.
12. Powell, RJ, Comerota, AJ, Berceli, SA, Guzman, R, Henry, TD, Tzeng, E et al. (2011). Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 54: 1032-1041.
13. Adam, DJ, Beard, JD, Cleveland, T, Bell, J, Bradbury, AW, Forbes, JF et al.; BASIL trial participants. (2005). Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 366: 1925-1934. (Pubitemid 41713982)
14. Conte, MS, Bandyk, DF, Clowes, AW, Moneta, GL, Seely, L, Lorenz, TJ et al.; PREVENT III Investigators. (2006). Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43: 742-751.
15. Murphy, MP, Lawson, JH, Rapp, BM, Dalsing, MC, Klein, J, Wilson, MG et al. (2011). Autologous bone marrow mononuclear cell therapy is safe and promotes amputationfree survival in patients with critical limb ischemia. J Vasc Surg 53: 1565-74.e1.
16. Perin, EC, Guilherme, S, Gahremanpour, A, Canales, J, Zheng, Y, Cabreira-Hansen, MG et al (2011). A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 78: 1060-1067.